BAK1 and Ewing sarcoma: In terms of drug resistance, miR-125b has been shown to increase cell resistance to doxorubicin and daunorubicin in leukemia and Ewing sarcoma by suppressing the expression of apoptotic mediators such as p53 and/or BAK1 (Bcl2 antagonist killer 1) [26, 27].